SG11202111672RA - Cancer associated antibody compositions and methods of use - Google Patents
Cancer associated antibody compositions and methods of useInfo
- Publication number
- SG11202111672RA SG11202111672RA SG11202111672RA SG11202111672RA SG11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA SG 11202111672R A SG11202111672R A SG 11202111672RA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- cancer associated
- antibody compositions
- associated antibody
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (25)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840904P | 2019-04-30 | 2019-04-30 | |
| US201962840864P | 2019-04-30 | 2019-04-30 | |
| US201962840870P | 2019-04-30 | 2019-04-30 | |
| US201962840957P | 2019-04-30 | 2019-04-30 | |
| US201962840880P | 2019-04-30 | 2019-04-30 | |
| US201962840917P | 2019-04-30 | 2019-04-30 | |
| US201962840640P | 2019-04-30 | 2019-04-30 | |
| US201962840858P | 2019-04-30 | 2019-04-30 | |
| US201962840638P | 2019-04-30 | 2019-04-30 | |
| US201962840875P | 2019-04-30 | 2019-04-30 | |
| US201962840950P | 2019-04-30 | 2019-04-30 | |
| US201962840938P | 2019-04-30 | 2019-04-30 | |
| US201962841036P | 2019-04-30 | 2019-04-30 | |
| US201962840855P | 2019-04-30 | 2019-04-30 | |
| US201962840860P | 2019-04-30 | 2019-04-30 | |
| US201962840861P | 2019-04-30 | 2019-04-30 | |
| US201962841044P | 2019-04-30 | 2019-04-30 | |
| US201962840893P | 2019-04-30 | 2019-04-30 | |
| US201962840648P | 2019-04-30 | 2019-04-30 | |
| US201962841049P | 2019-04-30 | 2019-04-30 | |
| US201962841047P | 2019-04-30 | 2019-04-30 | |
| US201962840970P | 2019-04-30 | 2019-04-30 | |
| US201962840909P | 2019-04-30 | 2019-04-30 | |
| US201962840644P | 2019-04-30 | 2019-04-30 | |
| PCT/US2020/030534 WO2020223392A2 (en) | 2019-04-30 | 2020-04-29 | Cancer associated antibody compositions and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202111672RA true SG11202111672RA (en) | 2021-11-29 |
Family
ID=73029242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202111672RA SG11202111672RA (en) | 2019-04-30 | 2020-04-29 | Cancer associated antibody compositions and methods of use |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220204643A1 (zh) |
| EP (1) | EP3962953A4 (zh) |
| JP (1) | JP2022530667A (zh) |
| CN (1) | CN114127114A (zh) |
| AU (1) | AU2020266560A1 (zh) |
| CA (1) | CA3138550A1 (zh) |
| SG (1) | SG11202111672RA (zh) |
| WO (1) | WO2020223392A2 (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021395241A1 (en) * | 2020-12-07 | 2023-06-22 | Target Discovery Merger Sub II, LLC | Systems and methods for producing disease-associated protein compositions |
| EP4291232A2 (en) * | 2021-02-12 | 2023-12-20 | Merck Sharp & Dohme LLC | Antibodies that bind metapneumovirus, antigenic metapneumovirus proteins, and uses thereof |
| CN117186218B (zh) * | 2023-09-06 | 2024-04-30 | 十堰市太和医院（湖北医药学院附属医院） | 一种靶向rbm47的纳米抗体及其制备方法 |
| CN117625626B (zh) * | 2024-01-25 | 2024-04-16 | 中国农业科学院植物保护研究所 | RNAi在提高苏云金芽胞杆菌杀虫蛋白防治二化螟或草地贪夜蛾效果中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2580241B1 (en) * | 2010-06-09 | 2020-11-04 | Queen Mary & Westfield College, University of London | Annexin 1 antibody |
| US20140206574A1 (en) * | 2011-08-31 | 2014-07-24 | Karen Chapman | Methods and Compositons for the Treatment and Diagnosis of Cancer |
| US20150044224A1 (en) * | 2012-03-02 | 2015-02-12 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Materials and methods for differential treatment of cancer |
| CA3051222C (en) * | 2013-06-10 | 2023-01-24 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for reducing immunosupression by tumor cells |
| US11040111B2 (en) * | 2014-03-03 | 2021-06-22 | Academia Sinica | Bi-specific antibodies and uses thereof |
| JP2018507254A (ja) * | 2015-02-02 | 2018-03-15 | アイツー ファーマシューティカルズ， インコーポレーテッド | 抗代替軽鎖抗体 |
| EP3448987A4 (en) * | 2016-04-29 | 2020-05-27 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF DISEASES |
| GB201702091D0 (en) * | 2017-02-08 | 2017-03-22 | Medannex Ltd | Specific binding molecules |
| CN118126157A (zh) * | 2017-08-03 | 2024-06-04 | 美国安进公司 | 白介素-21突变蛋白和治疗方法 |
-
2020
- 2020-04-29 AU AU2020266560A patent/AU2020266560A1/en active Pending
- 2020-04-29 CN CN202080048070.8A patent/CN114127114A/zh active Pending
- 2020-04-29 JP JP2021564804A patent/JP2022530667A/ja active Pending
- 2020-04-29 US US17/606,246 patent/US20220204643A1/en active Pending
- 2020-04-29 WO PCT/US2020/030534 patent/WO2020223392A2/en unknown
- 2020-04-29 SG SG11202111672RA patent/SG11202111672RA/en unknown
- 2020-04-29 CA CA3138550A patent/CA3138550A1/en active Pending
- 2020-04-29 EP EP20798045.9A patent/EP3962953A4/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3138550A1 (en) | 2020-11-05 |
| EP3962953A2 (en) | 2022-03-09 |
| WO2020223392A3 (en) | 2020-12-10 |
| WO2020223392A2 (en) | 2020-11-05 |
| EP3962953A4 (en) | 2023-08-23 |
| US20220204643A1 (en) | 2022-06-30 |
| JP2022530667A (ja) | 2022-06-30 |
| AU2020266560A1 (en) | 2021-11-25 |
| CN114127114A (zh) | 2022-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL288754A (en) | Preparations and methods for cancer immunotherapy | |
| IL280963A (en) | Anti-5gdf1 antibodies, compounds and methods of use | |
| ZA202102034B (en) | Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies | |
| IL278772A (en) | Antibodies against 40-OX and methods of use | |
| SG11202111672RA (en) | Cancer associated antibody compositions and methods of use | |
| IL287282A (en) | Anti-mertk antibodies and methods of using them | |
| IL290741A (en) | Antibodies against cd-96 and methods of using them | |
| ZA202100780B (en) | Bismuth-thiol compositions and methods of use | |
| IL276135A (en) | Preparations and methods of use | |
| SG11202108734VA (en) | Anti-trem2 antibodies and methods of use thereof | |
| IL277212A (en) | Anti-KLK5 antibodies and methods of use | |
| IL289952A (en) | Anti-ms4a4a antibodies and methods of using them | |
| IL285401A (en) | Anti-clec2d antibodies and methods of using them | |
| IL291730A (en) | Protein-macromolecule conjugates and methods for using them | |
| IL280280B1 (en) | Formulations of FCRN antibodies and methods of using them | |
| IL285247A (en) | Improved nitrate rents and methods of their use | |
| IL291461A (en) | Anti-alpha-synuclein antibodies and methods of using them | |
| IL283076A (en) | Methods and preparations for cancer immunotherapy | |
| IL276203A (en) | Compounds and methods for treating cancer | |
| SG11202106295WA (en) | Compositions and methods for cancer therapy | |
| IL288886A (en) | Antibodies and methods of use | |
| IL289334A (en) | New cancer antigens and methods | |
| IL289335A (en) | New cancer antigens and methods | |
| IL289200A (en) | New cancer antigens and methods | |
| IL289205A (en) | New cancer antigens and methods |